Prolia 60 mg Solution for subcutaneous injection.
PDF Leaflet Revision Date: 02 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of osteoporosis and bone loss in specific populations.
Dosage (summary)
60 mg subcutaneously every 6 months; no adjustment for elderly or renal impairment.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; potential risks in breastfeeding.
Key Drug Interactions
- CYP3A4 substrates
- Hormone replacement therapy
Contraindications
- Hypersensitivity
- Hypocalcaemia
Common side effects
- Musculoskeletal pain
- Cellulitis
- Hypocalcaemia
Counselling Points
- Ensure adequate calcium and vitamin D intake
- Monitor for signs of hypocalcaemia
- Report any unusual thigh or hip pain
Serious warnings
- Severe hypocalcaemia
- Osteonecrosis of the jaw
- Atypical femoral fractures
Important Disclaimer
The Prolia 60 mg Solution for subcutaneous injection. professional information leaflet below is the property of Amgen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
